- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT07727512
PCOS and Brain Health
Functional and Structural Impacts of Polycystic Ovary Syndrome (PCOS) on Brain Health
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
Aim 1: To determine whether individuals with PCOS exhibit reduced CBF at global, lobe and regional brain levels.
Aim 2: To assess whether individuals with PCOS have alterations in brain structure including grey and white volume, cortical thickness, or connectivity compared to controls.
Aim 3: To evaluate whether individuals with PCOS demonstrate impairments in cognitive performance, including verbal fluency, memory, and processing speed, relative to controls.
Aim 4: To characterize systemic immune cell states, circulating inflammatory and metabolic profiles, and epigenomic regulatory landscapes in peripheral blood of individuals with and without PCOS, and to evaluate whether these multiomic signatures are associated with CBF, brain structure, connectivity, and cognitive performance.
Studientyp
Einschreibung (Geschätzt)
Kontakte und Standorte
Studienkontakt
- Name: Sharon Blohowiak
- Telefonnummer: (608) 262-5977
- E-Mail: sblohowiak@wisc.edu
Studienorte
-
-
Wisconsin
-
Madison, Wisconsin, Vereinigte Staaten, 53792
- Rekrutierung
- University of Wisconsin
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
- Erwachsene
Akzeptiert gesunde Freiwillige
Probenahmeverfahren
Studienpopulation
Beschreibung
Inclusion Criteria (Participants with PCOS):
Rotterdam criteria demonstrating two out of the three criteria. These are:
- Presence of clinical hyperandrogenism or biochemical hyperandrogenism
- A history of irregular menstrual cycles
- Presence of polycystic ovarian morphology on ultrasound
Inclusion Criteria (Healthy Controls):
- Regular menstrual cycles (not meeting criteria for irregular cycles above)
- No diagnosis of PCOS
- Controls may have isolated hirsutism or polycystic ovaries on ultrasound as long as they do not meet Rotterdam criteria for PCOS
Exclusion Criteria:
- Current pregnancy
- Preexisting diagnosis of type 1 diabetes
- Severe obesity (body mass index (BMI) greater than 45kg/m2)
- Preexisting diagnosis of hypertension requiring antihypertensive medication or blood pressure of greater than 160/100 on two separate occasions during clinical care
- History of neurologic disease or stroke
- History of myocardial infarction or deep venous thrombosis
- Endometriosis confirmed by prior laparoscopy
- Autoimmune conditions including lupus, multiple sclerosis, and active malignancy
- Immuno-modulating medications
Conditions incompatible with MRI scanning, including but not limited to
- Certain implanted metal devices or foreign bodies
- Severe claustrophobia
- Post-menopausal
- Participants will be excluded if they have taken hormonal contraception or fertility medication in the last month
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
Kohorten und Interventionen
Gruppe / Kohorte |
Intervention / Behandlung |
|---|---|
|
Participants with PCOS
N=30 participants recruited
|
MRI visit will take approximately 1.5 hour (55-60 minutes in MRI) and will involve structural scans of the brain, and scans at rest and while performing cognitive tasks.
Andere Namen:
DEXA scan for obtaining body composition, NIH toolbox to assess cognitive test, and optional graded exercise test (GXT).
|
|
Healthy Controls
N=15 age and BMI-matched participants recruited
|
MRI visit will take approximately 1.5 hour (55-60 minutes in MRI) and will involve structural scans of the brain, and scans at rest and while performing cognitive tasks.
Andere Namen:
DEXA scan for obtaining body composition, NIH toolbox to assess cognitive test, and optional graded exercise test (GXT).
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Cerebral Blood Flow (CBF) at rest
Zeitfenster: data collected during a 2-hour MRI visit (anytime up to 3 months on study)
|
Arterial Spin Labeling (ASL) color atlases and 4D Flow MRI will be used to measure CBF at rest.
CBF will be measured in each of six brain regions: temporal, parietal, frontal, occipital, subcortical, and brainstem.
|
data collected during a 2-hour MRI visit (anytime up to 3 months on study)
|
|
Circulating Sex Hormone Levels
Zeitfenster: data collected during a 2-hour MRI visit (anytime up to 3 months on study)
|
data collected during a 2-hour MRI visit (anytime up to 3 months on study)
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Body composition via DEXA scan
Zeitfenster: data collected during a 2-hour lab visit (anytime up to 3 months on study)
|
Percent body fat and lean mass to be measured via Dual-Energy X-ray Absorptiometry (DEXA) scan.
|
data collected during a 2-hour lab visit (anytime up to 3 months on study)
|
|
NIH Toolbox: Dimensional Change Card Sort Test
Zeitfenster: data collected during a 2-hour lab visit (anytime up to 3 months on study)
|
NIH Toolbox to assess neurocognitive function.
The Dimensional Change Card Sort Test measures accuracy: the number of accurate responses, up to a maximum of 40.
|
data collected during a 2-hour lab visit (anytime up to 3 months on study)
|
|
NIH Toolbox: Pattern Comparison Processing Speed Test
Zeitfenster: data collected during a 2-hour lab visit (anytime up to 3 months on study)
|
NIH Toolbox to assess neurocognitive function.
The Pattern Comparison Processing Speed Test measures how many correct responses the participant has within 90 seconds.
There is a maximum of 130 items.
|
data collected during a 2-hour lab visit (anytime up to 3 months on study)
|
|
NIH Toolbox: Flanker Inhibitory Control and Attention
Zeitfenster: data collected during a 2-hour lab visit (anytime up to 3 months on study)
|
NIH Toolbox to assess neurocognitive function.
The Flanker test is a measure of executive function and is scored using a T-score where 100 is the average, higher scores indicate better performance.
|
data collected during a 2-hour lab visit (anytime up to 3 months on study)
|
|
Cardiorespiratory fitness (VO2max) [Optional]
Zeitfenster: data collected during a 2-hour lab visit (anytime up to 3 months on study)
|
data collected during a 2-hour lab visit (anytime up to 3 months on study)
|
Mitarbeiter und Ermittler
Sponsor
Ermittler
- Hauptermittler: Laura Cooney, MD, University of Wisconsin, Madison
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
- Urogenitale Erkrankungen
- Genitalerkrankungen
- Erkrankungen des endokrinen Systems
- Neubildungen
- Weibliche Urogenitalerkrankungen
- Weibliche Urogenitalerkrankungen und Schwangerschaftskomplikationen
- Genitalerkrankungen, weiblich
- Eierstockerkrankungen
- Adnexerkrankungen
- Gonadenstörungen
- Eierstockzysten
- Zysten
- PCO-Syndrom
- Diagnosetechniken und Verfahren
- Diagnose
- Tomographie
- Diagnostische Bildgebung
- Magnetresonanztomographie
Andere Studien-ID-Nummern
- 2026-0690
- Protocol Version 6/29/2026 (Andere Kennung: UW Madison)
- SMPH / Reproductive Endo (REI) (Andere Kennung: UW Madison)
- ICTR Pilot Award (Andere Zuschuss-/Finanzierungsnummer: NCATS)
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .